Charles Arnold - Stemtech CEO Director
| STEK Stock | USD 0.05 0 2.64% |
Insider
Charles Arnold is CEO Director of Stemtech
| Age | 71 |
| Phone | 954 715 6000 |
| Web | https://www.stemtech.com |
Stemtech Management Efficiency
The company has return on total asset (ROA) of (0.7542) % which means that it has lost $0.7542 on every $100 spent on assets. This is way below average. Stemtech's management efficiency ratios could be used to measure how well Stemtech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | INSIDER Age | ||
| Damon Terrill | Alpha Teknova | 53 | |
| Lisa McCann | Alpha Teknova | 42 | |
| Damian Finio | Phibro Animal Health | 54 | |
| Ken Gelhaus | Alpha Teknova | 40 | |
| Matthew Lowell | Alpha Teknova | 54 | |
| Jean Filippi | Phibro Animal Health | N/A | |
Management Performance
| Return On Asset | -0.75 |
Stemtech Leadership Team
Elected by the shareholders, the Stemtech's board of directors comprises two types of representatives: Stemtech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stemtech. The board's role is to monitor Stemtech's management team and ensure that shareholders' interests are well served. Stemtech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stemtech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Arnold, CEO Director | ||
| James Cardwell, Chief Officer | ||
| Alejandro Carrillo, Managing Markets | ||
| John Meyer, COO Pres |
Stemtech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Stemtech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.75 | |||
| Profit Margin | (1.85) % | |||
| Operating Margin | (1.34) % | |||
| Current Valuation | 8.79 M | |||
| Shares Outstanding | 48.63 M | |||
| Shares Owned By Insiders | 63.60 % | |||
| Price To Sales | 1.54 X | |||
| Revenue | 4.32 M | |||
| Gross Profit | 3.3 M | |||
| EBITDA | 1.58 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.